Articles

  1. Eliminating Antibiotic Resistance Gene Transfer Risks In CGTs 8/14/2023

    Learn about the drawbacks of antibiotic resistance that can cause side effects in patients and how an antibiotic-free approach can ease the burden of regulatory compliance and accelerate development.

  2. API In Capsule Vs. The Lost Art Of Formulation Development 5/5/2020

    Very few businesses have as specialized a set of needs as those in the pharmaceutical sector. The combination of huge product development costs, large amounts of data and intense regulatory control makes it critical for companies to have needed information as soon as possible in order to meet a varied and closely monitored set of business processes. By Todd Daviau, Ph.D

  3. Can CROs Help Reduce The Expense Of Clinical Trials? 4/29/2014

    Figures reported by the Tufts Center for the Study of Drug Development state that the average capitalized cost of bringing a new drug to market is about $1.3B. Compare that to the 1991 cost of $318M, and after adjusting the amount for general inflation, it shows a 260% increase over the course of two decades in the cost of developing a drug. Industry data relays that the bulk of drug development costs are incurred during clinical trials, often, Phase 3 trials.

  4. Brochure: Norwich Clinical Services 2/1/2013

    Norwich Clinical Services is a contract research organization that provides Bioanalytical Services, Pharmacovigilance and Clinical Research Programs to the pharmaceutical and biotech industries.

  5. Developing A Strategic Relationship – Amgen And PRA 6/21/2012

    When new opportunities arise and sponsor companies are vetting CROs or partners for their work, they look first to their existing relationships. Then, particularly for new development areas such as biosimilars, they look at the entire landscape for other organizations that have specific expertise in that field. By Rob Wright

  6. Why Choosing The Right Digital Collaboration Program Is Critical To Future Success 5/30/2012

    Increasing drug development costs, longer trial durations and insufficient rates of success are prompting the search for innovative solutions for clinical trials. As sponsors seek new ways to mitigate risks and maximize opportunities in clinical development efficiencies, many are turning to a digital collaboration platform. By Within3

  7. What Do Consultants Look For When Advising Drug Development Companies On CRO Selection? 5/16/2012

    L.E.K., founded in 1983, is a global strategy consulting firm with offices across Europe, the Americas, and Asia-Pacific. One of its more than 900 employees, Jonathan Kfoury, functions as the VP of L.E.K.’s Boston office, with a focus on R&D, partnership, and commercialization strategy development for biopharmaceutical and medical technology companies. By Rob Wright

  8. A Chief Medical Officer's Perspective On Selecting A CRO 5/14/2012

    Santosh Vetticaden, Ph.D., M.D. is a drug development professional with over 20 years of experience spanning large pharma and biotech across multiple therapeutic areas. He has been involved in trials from Phase I-Phase IV and has been extensively involved in the design, planning, and implementation of global trials. By Rob Wright, Chief Editor, Life Science Leader magazine

  9. Adding Value To The Drug Development Process 4/30/2012

    Life science companies can gain advantages from working with external partners that can bridge the divide between drug development and commercialization. By William Crown, Ph.D.

  10. Kemwell Overview 3/29/2012
    Manufacturing customers include top pharmaceutical companies – Allergan, Bayer, GSK, J&J, Pfizer, Teva, and Novartis, as well as small emerging biotech.